Skip to main
  1. Stocks
  2. Palvella Therapeutics Inc
  3. Forecast
PVLA

PVLA Stock Forecast & Price Target

PVLA Analyst Ratings

Based on 13 analyst ratings
Strong Buy
Strong Buy 69%
Buy 31%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Palvella Therapeutics is viewed positively because its lead asset, QTORIN 3.9% rapamycin gel, has already cleared a major clinical hurdle in mLMs, where Phase 3 SELVA met its primary and all prespecified secondary endpoints, and FDA accepted the NDA for Priority Review with a February 28, 2027 PDUFA date. The thesis is strengthened by a rare-disease platform with limited competition, a localized and non-immunosuppressive delivery approach, and a market-creation strategy that could address multi-thousand-patient opportunities, with modeled gross peak sales of about $1.4B for mLMs, $2.1B for cVMs, and $900M each for CSAs and DSAP. Additional upside comes from a focused commercial launch setup, 166 mapped sites, roughly 400 initial targets, and multiple upcoming catalysts in 4Q26 and 2027 that could broaden the platform beyond the first approval.

Bears say

Palvella Therapeutics is facing a fundamentally fragile setup because its novel QTORIN platform still has to prove that localized delivery can generate consistent, clinically meaningful results across multiple indications and payloads. The lead programs rest on single-arm, baseline-controlled studies and novel endpoints, while FDA uncertainty, narrower-label risk, and prior delays in CMC or inspection issues all raise the odds of added studies and slower approval. Even if approved, commercialization is challenged by a small specialized patient base, entrenched cheaper alternatives, a $250.6M cash position paired with a runway of only at least 12 months, likely dilution, and 8.0%-9.8% Ligand royalties that compress economics.

PVLA has been analyzed by 13 analysts, with a consensus rating of Strong Buy. 69% of analysts recommend a Strong Buy, 31% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Palvella Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

PVLA Analyst Forecast & Price Prediction

Get the latest PVLA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in PVLA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Palvella Therapeutics Inc (PVLA) Forecast

Analysts have given PVLA a Strong Buy based on their latest research and market trends.

According to 13 analysts, PVLA has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $209, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $209, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Palvella Therapeutics Inc (PVLA)


PVLA Analyst Forecast & Price Prediction

Get the latest PVLA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in PVLA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover PVLA stock data and trends